Renaissance Technologies
ZBIO

Renaissance Technologies’s Zenas BioPharma ZBIO Stock Holding History

Renaissance Technologies’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-38,400
Closed -$314K – 3931
2024
Q4 		$314K Buy
+38,400
New +$599K ﹤0.01% 3025

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Renaissance Technologies's ZBIO Position: Q1 2025 in Review

Renaissance Technologies sold out of Zenas BioPharma (ZBIO) in Q1 2025, closing a stake of 38,400 shares — an estimated $314K sold.

Renaissance Technologies first reported a position in ZBIO in Q4 2024 and held it in 1 quarter. The position peaked at $314K in Q4 2024. 67 funds tracked by Wall St. Rank hold ZBIO as of Q1 2025.

  • Renaissance Technologies reported no remaining Zenas BioPharma position as of Q1 2025 after selling out during the quarter.
  • Renaissance Technologies sold 38,400 Zenas BioPharma shares in Q1 2025, an estimated $314K.
  • Renaissance Technologies first reported a position in Zenas BioPharma in Q4 2024 and held it in 1 quarter.
  • Renaissance Technologies's Zenas BioPharma position peaked at $314K in Q4 2024.
  • 67 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.